HBLYX | MROSX | HBLYX / MROSX | |
Total Expense Ratio | 0.67 | 0.69 | 97% |
Annual Report Gross Expense Ratio | 0.67 | 0.69 | 97% |
Fund Existence | 19 years | 14 years | - |
Gain YTD | 4.081 | 3.657 | 112% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250000 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 11.8B | 182M | 6,484% |
Annual Yield % from dividends | 3.53 | 3.26 | 108% |
Returns for 1 year | 4.74 | 5.99 | 79% |
Returns for 3 years | 16.70 | 16.76 | 100% |
Returns for 5 years | 17.48 | 12.81 | 136% |
Returns for 10 years | 40.09 | 19.00 | 211% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
AZNAX | 11.06 | -0.07 | -0.63% |
Virtus Income & Growth A | |||
FBTCX | 20.46 | -0.13 | -0.63% |
Fidelity Advisor Biotechnology C | |||
MSCUX | 11.89 | -0.15 | -1.25% |
Morgan Stanley American Resilience A | |||
NGRRX | 33.08 | -0.43 | -1.28% |
Nuveen International Value I | |||
MNHCX | 25.58 | -0.40 | -1.54% |
Manning & Napier Pro-Blend Max Term L |